Literature DB >> 27098812

Real-life management of primary immune thrombocytopenia (ITP) in adult patients and adherence to practice guidelines.

María Luisa Lozano1, N Revilla2,3, T J Gonzalez-Lopez4, S Novelli5, J R González-Porras6, B Sánchez-Gonzalez7, N Bermejo8, S Pérez9, F J Lucas10, M T Álvarez11, M J Arilla12, M Perera13, J do Nascimento14, R M Campos15, L F Casado16, V Vicente2.   

Abstract

Very few data exist on the management of adult patients diagnosed with primary immune thrombocytopenia (ITP). The objectives of this study were to describe the diagnostic and treatment patterns for ITP and to compare the findings to recent ITP guidelines. We retrospectively analyzed the medical records of adult ITP patients diagnosed with primary ITP between January 2011 and June 2012 and examined whether management strategies were consistent or not with eight recent guideline-recommended practices. Overall, median age at the diagnosis of the disease (n = 101) was 58 years and median platelet count 12 × 10(9)/L with 75.2 % of patients having symptoms of ITP. The study perceived two major shortcomings in the diagnostic approach: (1) failure to perform peripheral blood film examination in 22.8 % of patients, a test that is mandatory by all guidelines, and (2) ordinary bone marrow assessment in more than half of the patients at diagnosis (50.5 %), a test not routinely recommended by guidelines. Low appropriateness in therapeutic management of patients included (1) unjustified use of intravenous immunoglobulin in the absence of bleeding in 54.8 % of patients and (2) splenectomy not being deferred until 6-12 months from diagnosis (median 161 days). Data also reflect a trend towards the early use of thrombopoietin receptor agonists in the treatment of patients who are refractory to any first-line therapy. We have recognized important areas of inapropriateness in the diagnostic and therapeutic management of adult ITP patients. Compliance with established guidelines should be encouraged in order to improve patient outcomes.

Entities:  

Keywords:  Guidelines; ITP; Primary immune thrombocytopenia; Real-life practice; Splenectomy; Thrombopoietin receptor agonists

Mesh:

Year:  2016        PMID: 27098812     DOI: 10.1007/s00277-016-2665-3

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  5 in total

1.  Why do we overtreat children with immune thrombocytopenia despite existing evidence-based guidelines?

Authors:  Wolfgang R Eberl
Journal:  Blood Transfus       Date:  2020-09       Impact factor: 3.443

2.  Efficacy and tolerability of old and new drugs used in the treatment of immune thrombocytopenia: Results from a long-term observation in clinical practice.

Authors:  Fabian Depré; Nasra Aboud; Beate Mayer; Abdulgabar Salama
Journal:  PLoS One       Date:  2018-06-01       Impact factor: 3.240

3.  Treatment Patterns Among Adults with Primary Immune Thrombocytopenia Diagnosed in Hematology Clinics in the United States.

Authors:  Leah J McGrath; Karynsa Kilpatrick; Robert A Overman; Diane Reams; Anjali Sharma; Ivy Altomare; Jeffrey Wasser; M Alan Brookhart
Journal:  Clin Epidemiol       Date:  2020-05-05       Impact factor: 4.790

4.  Management of Adult Patients with Primary Immune Thrombocytopenia (ITP) in Clinical Practice: A Consensus Approach of the Spanish ITP Expert Group.

Authors:  M Eva Mingot-Castellano; M Teresa Álvarez Román; Luis Fernando Fernández Fuertes; Tomás José González-López; José María Guinea de Castro; Isidro Jarque; M Fernanda López-Fernández; Maria Luisa Lozano; Blanca Sánchez González; David Valcárcel Ferreiras; José Ramón González Porras
Journal:  Adv Hematol       Date:  2019-08-22

5.  Combination peptide immunotherapy suppresses antibody and helper T-cell responses to the major human platelet autoantigen glycoprotein IIb/IIIa in HLA-transgenic mice.

Authors:  Lindsay S Hall; Charlotte S Lennon; Andrew M Hall; Stanislaw J Urbaniak; Mark A Vickers; Robert N Barker
Journal:  Haematologica       Date:  2018-12-04       Impact factor: 9.941

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.